Skip to main content

Table 1 Baseline demographic characteristics of N = 15 subjects

From: Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

Age (years)

52 (38–61)

BMI

 < 30

6 (40%)

 > 30

9 (60%)

Sex

Female

14 (93.3%)

Male

1 (6.7%)

Ethnicity

Hispanic or Latino

4 (26.6%)

Not Hispanic or Latino

11 (73.3%)

Race

Black or African American

1 (6.7%)

White

14 (93.3%)

Concomitant medications

DMARDs or Glucocorticoids

13 (86.7%)

Biologic DMARDs

12 (80%)

Synthetic DMARDs

10 (66.7%)

Glucocorticoids

6 (40%)

Disease duration (years)

 

11.4 (6.20–26.4)

  1. BMI, body mass index; DMARDs, disease modifying anti-rheumatic drugs statistics represented: median (IQR); n (%)